Sana Biotechnology Inc (SANA) Stock Price Today
Aura AI Summary
Key Stats
- $918.36MMarket Cap
- -Volume
- HealthSector
- $5.9252W High
- $2.6852W Low
- -Typical Hold Time
- $892.55MEnterprise Value
- -Div Yield
- -Trading Activity
Track Sana Biotechnology Inc (SANA) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Sana Biotechnology Inc has traded between a low of $2.68 and a high of $5.92, highlighting its annual price range. Buy and sell Sana Biotechnology Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Most Recent News
NewHydrogen plans to use nuclear heat to produce clean hydrogen at industrial scale, bypassing costly electricity use.
NewHydrogen announced its plan to pair its ThermoLoop technology with heat from small modular nuclear reactors (SMRs) to produce clean hydrogen at industrial scale. This approach uses high-temperature nuclear heat to split water thermochemically, avo...

Altisource CEO buys shares amid 19% revenue rise and AI-driven efficiency boost
Altisource Portfolio Solutions' CEO Shepro William B purchased 4,000 shares, increasing his stake to 8,686 shares, signaling confidence in the company's future. The company reported a 19% year-over-year increase in Q2 2026 service revenue to $48.70 m...

Access barriers limit Xphozah uptake despite nephrologists' willingness to triple use, with reimbursement changes ahead.
New research from Spherix Global Insights reveals that access barriers, not drug efficacy, restrict the use of Ardelyx's Xphozah for dialysis patients with hyperphosphatemia. Nephrologists say they would nearly triple Xphozah prescriptions if reimbur...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.